Why Prior Auth Turnaround Times Vary by Payer — And What You Can Do About It
Why Prior Auth Turnaround Times Vary by Payer — And What You Can Do About It
Two patients. Same biologic. Same diagnosis severity. One gets approved in 48 hours. The other waits 19 days.
The clinical cases are identical. The payers aren't.
Prior auth turnaround time is one of the most frustrating variables in specialty practice because it feels arbitrary — and often is. But there are patterns worth understanding. Once you know why the gaps exist, you can actually do something about them.
The Regulatory Baseline (And Why It Doesn't Help Much)
CMS sets turnaround time requirements for Medicare Advantage plans, and 2024 rule updates tightened those mandates significantly:
- Standard PA decisions: 7 calendar days from receipt of all required information
- Expedited (urgent) decisions: 72 hours
Those are the floors for MA plans. The catch: "receipt of all required information" is doing a lot of work in that sentence. If the payer's system flags your submission as incomplete — missing a lab value, a prior treatment date, a diagnosis code — the clock doesn't start until you respond. A submission that bounces for additional information twice can easily eat 2-3 weeks even under technically compliant timelines.
Commercial payers are not subject to the same CMS mandates. State insurance regulations fill some of the gap — most states require standard PA decisions within 14 business days — but enforcement is inconsistent and the variation between states is real.
Health Affairs research documented average PA turnaround times across payer types ranging from 3 days (best-performing commercial plans) to 21+ days (some state Medicaid programs for specialty drugs).
Why Medicare Advantage Is Often Slower Than It Should Be
MA plans have the tightest regulatory requirements but frequently produce the most frustrating delays in practice. The paradox has a few explanations.
First, MA plans cover a disproportionately complex patient population — older patients, more comorbidities, more specialty medications. PA volume is high and the cases are complicated.
Second, the 7-day clock gives plans multiple opportunities to pause. Requests for additional clinical information reset the window. A plan that is slow to ask follow-up questions — and then slow to process your response — can stretch a 7-day mandate into a 3-week process without technically violating it.
Third, many MA plans outsource utilization management to third-party vendors. You're not dealing directly with Humana or United when you submit a PA — you're dealing with their UM contractor, which may have different staffing, different queues, and different internal timelines.
Why Commercial Payer Times Vary So Widely
Commercial turnaround times depend heavily on:
Submission channel. Electronic PA submissions consistently process faster than fax. CoverMyMeds benchmark data shows electronic submissions averaging 2-5 days to decision; fax submissions averaging 9-14 days for the same drug category. The difference is almost entirely queue processing time, not clinical review time.
Drug category. Standard medications on a payer's preferred drug list can get real-time auto-approvals. Specialty and biologic drugs require human clinical review. That step adds days, sometimes more than a week.
Documentation completeness. Incomplete submissions are the single biggest cause of extended timelines. A complete submission reviewed by a clinical team resolves faster than an incomplete submission that bounces between the payer and your office twice. Most commercial plans don't restart the clock in your favor when they request additional information.
Time of year. This one surprises people. PA volume spikes in January when plan years reset and patients hit new deductibles. Payer review queues get backed up. Turnaround times in January and February are routinely longer than July or August.
Medicaid: The Widest Variation of All
Medicaid turnaround times are the least predictable category — and for practices with a significant Medicaid patient population, that's a serious operational issue.
State Medicaid programs have widely different infrastructure. Some have modernized to electronic submission and real-time systems. Others are still running manual review processes with turnaround times of 3-4 weeks for specialty drugs. The federal minimum standards for Medicaid managed care PA timelines exist, but state-by-state implementation varies substantially.
The specialty drug category is particularly acute. CMS Medicaid guidance requires states to have PA processes, but leaves significant discretion to states on timing. For practices in states with less modernized Medicaid infrastructure, building extra lead time into biologic PA workflows isn't optional — it's survival.
What Actually Speeds Things Up
There are variables you can't control — which payer the patient has, which state you're in, what time of year it is. But there are also variables you can control, and they matter more than most practices realize.
Submit electronically whenever possible. The 5-7 day difference between electronic and fax submission is consistent across payer types. If your EHR or a clearinghouse offers electronic PA submission for a given payer, use it every time.
Know each payer's specific submission requirements before you submit. This sounds basic. It's not. United, Aetna, Humana, and Blue Cross each publish clinical coverage policies for specific biologics. Those policies change. What was required for adalimumab under Aetna's 2024 policy may differ from 2026. Build a process for keeping those requirements current.
Submit complete documentation on the first attempt. Every request for additional information adds days — sometimes weeks. The math is unforgiving: one bounce costs you at least 3-5 business days. Two bounces can eat your entire regulatory window. Complete, specific documentation on first submission is the highest-leverage thing you can do to control turnaround time.
Request expedited review when clinically appropriate. If delaying treatment would seriously jeopardize the patient's health, you're entitled to the 72-hour expedited track under MA rules. Document the urgency specifically. "Patient needs treatment soon" won't get you expedited status. "Delaying treatment risks hospitalization given current disease activity score of X" might.
Track turnaround times by payer. Most practices don't do this, which means they can't identify which payers are consistently slow and adjust their submission timelines accordingly. A simple log of submission date, decision date, and payer type gives you data to work with within a few months.
The Documentation Connection
Here's the uncomfortable truth about turnaround times: a significant portion of delay is self-inflicted.
Not intentionally. But the documentation gaps that trigger requests for additional information — missing prior treatment history, undocumented lab values, vague disease activity descriptions — add days to every case they touch. Practices with high first-submission completion rates consistently report faster turnaround times than comparable practices with incomplete initial submissions.
That's the core argument for investing in documentation quality before submission. Tools like Luma are built specifically around this problem — generating documentation that addresses payer-specific criteria completely on the first submission, which means fewer bounces and faster decisions. The bottleneck shifts from your office back to the payer, where you at least have regulatory timelines on your side.
State Regulators: An Underused Lever
If a payer is consistently exceeding state-mandated turnaround times, you have options beyond just waiting.
Most state insurance departments have complaint processes for PA delays. Filing a complaint creates a paper trail and — in states with active enforcement — can generate meaningful pressure on the payer. The NAIC maintains a directory of state insurance commissioners with complaint filing information.
This isn't a practical tool for every delayed case. But for payers that are systematically slow and affecting multiple patients, a pattern of state complaints is more effective than phone calls to the payer's PA hotline.
The Realistic Expectation
Perfect turnaround times don't exist. But 48-hour decisions are real for well-submitted electronic PAs with the right payers. And 3-week waits are avoidable in most cases when documentation is complete and submission channels are optimized.
The practices that handle this best treat PA turnaround as a workflow management problem — track it, optimize the variables they control, and build patient communication systems that account for realistic timelines. That's not exciting operational advice. It's what actually works.
Sources:
Centers for Medicare & Medicaid Services. (2024). CMS Prior Authorization Rules for Medicare Advantage — 2024 Final Rule. cms.gov
Health Affairs. (2023). Prior Authorization Turnaround Times Across Payer Types. healthaffairs.org
CoverMyMeds. (2025). Prior Authorization Benchmark Report — Electronic vs. Fax Timelines. covermymeds.com
Centers for Medicare & Medicaid Services. (2025). Medicaid Prior Authorization Guidance. medicaid.gov
National Association of Insurance Commissioners. (2025). State Insurance Commissioner Directory. naic.org